ArticleScientific reports2026
Lipid nanoparticle delivery of circle RNA vaccine induces potent immune responses.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Circle RNA (circRNA) is a closed-loop nucleic acid resistant to exonuclease degradation. Their enhanced stability and potential for efficient protein expression through circRNA modification render them promising novel therapeutic agents for cancer treatment. In this study, we systematically investigated the antitumor and anti-inflammatory activities of circRNA vaccines in mice, as well as their effects on activating antigen-specific immune responses, through a meta-analysis. Subsequently, we further validated the immune-activating effects of circRNA using monocytes and T cells isolated from human peripheral blood mononuclear cells. We found that circRNA induces the activation and maturation of dendritic cells, as well as the responses of CD4 + and CD8 + T cells. These findings demonstrate the potential of circRNA to exert significant effects in therapeutic cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.